KMB Stock Analysis: Kimberly-Clark | NASDAQ
Household & Personal Products | NASDAQ, USA | Market Cap: 36.009m USD | 12M Return: -7.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 422M
EPS Trend: 88.0%
Qual. Beats: 0
Rev. Trend: -96.2%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kimberly-Clark Corporation manufactures and markets personal care products primarily in the United States, operating through two segments: North America and International Personal Care. Its product portfolio spans baby and child care (including disposable diapers, training pants, swimpants, and wipes), feminine and incontinence care, facial and bathroom tissue, paper towels, napkins, and wipers. The company sells well-known consumer brands such as Huggies, Pull-Ups, Kotex, Depend, Kleenex, Scott, Cottonelle, Viva, and WypAll, distributing household products through supermarkets, mass merchandisers, drugstores, warehouse clubs, and e-commerce channels. It also serves a professional/B2B market, supplying manufacturing, lodging, office, food service, and high-volume public facilities through distributors and direct sales. The company was founded in 1872 and is headquartered in Dallas, Texas.
As a large-cap consumer staples company in the household products sub-industry, Kimberly-Clark operates in a defensive sector characterized by relatively stable, recurring demand for essential personal care and hygiene goods. Its business model relies on a portfolio of legacy brands with strong household recognition, supported by dual distribution into both retail consumer channels and the away-from-home professional segment.
- Pulp and resin input costs pressure personal care margins
- International segment revenue pressured by emerging market FX volatility
- North America private label competition limits pricing power
| Net Income: 2.12b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 0.33 > 1.0 |
| NWC/Revenue: -9.75% < 20% (prev -9.04%; Δ -0.71% < -1%) |
| CFO/TA 0.19 > 3% & CFO 3.19b > Net Income 2.12b |
| Net Debt (6.67b) to EBITDA (3.06b): 2.18 < 3 |
| Current Ratio: 0.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (333.2m) vs 12m ago -0.03% < -2% |
| Gross Margin: 35.86% > 18% (prev 36.19%; Δ -0.33% > 0.5%) |
| Asset Turnover: 98.77% > 50% (prev 111.3%; Δ -12.50% > 0%) |
| Interest Coverage Ratio: 9.67 > 6 (EBIT TTM 2.42b / Interest Expense TTM 250.0m) |
| A: -0.09 (Total Current Assets 5.29b - Total Current Liabilities 6.90b) / Total Assets 17.2b |
| B: 0.57 (Retained Earnings 9.85b / Total Assets 17.2b) |
| C: 0.14 (EBIT TTM 2.42b / Avg Total Assets 16.7b) |
| D: 0.12 (Book Value of Equity 1.80b / Total Liabilities 15.3b) |
| Altman-Z'' = 2.35 = BBB |
| DSRI: 1.01 (Receivables 2.00b/2.18b, Revenue 16.5b/18.1b) |
| GMI: 1.01 (GM 36.19% / 35.86%) |
| AQI: 1.37 (AQ_t 0.29 / AQ_t-1 0.22) |
| SGI: 0.91 (Revenue 16.5b / 18.1b) |
| TATA: -0.06 (NI 2.12b - CFO 3.19b) / TA 17.2b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at USD 111.44 with a total of 2,516,078 shares traded. Over the past week, the price has changed by +2.73%, over one month by +1.39%, over three months by +14.98% and over the past year by -7.85%.
Current recommended Stop Loss: 107.80 (which is 3.3% or 1.4 ATR below the current price).
Kimberly-Clark has received a consensus analysts rating of 3.44. Therefore, it is recommended to hold KMB.
- StrongBuy: 3
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 116.1 | 4.2% |
P/E Trailing = 20.9826
P/E Forward = 14.4509
P/S = 2.175
P/B = 20.0255
P/EG = 2.1889
Revenue TTM = 16.5b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.06b USD
Long Term Debt = 6.47b USD (from longTermDebt, last quarter)
Short Term Debt = 609.0m USD (from shortTermDebt, last quarter)
Debt = 7.21b USD (from shortLongTermDebtTotal, last quarter) + Leases 128.0m
Net Debt = 6.67b USD (calculated: Debt 7.21b - CCE 542.0m)
Enterprise Value = 42.7b USD (36.0b + Debt 7.21b - CCE 542.0m)
Interest Coverage Ratio = 9.67 (Ebit TTM 2.42b / Interest Expense TTM 250.0m)
EV/FCF = 16.56x (Enterprise Value 42.7b / FCF TTM 2.58b)
FCF Yield = 6.04% (FCF TTM 2.58b / Enterprise Value 42.7b)
FCF Margin = 15.59% (FCF TTM 2.58b / Revenue TTM 16.5b)
Net Margin = 12.81% (Net Income TTM 2.12b / Revenue TTM 16.5b)
Gross Margin = 35.86% ((Revenue TTM 16.5b - Cost of Revenue TTM 10.6b) / Revenue TTM)
Gross Margin QoQ = 36.85% (prev 35.91%)
Tobins Q-Ratio = 2.48 (Enterprise Value 42.7b / Total Assets 17.2b)
Interest Expense / Debt = 3.47% (Interest Expense 250.0m / Debt 7.21b)
Taxrate = 23.63% (526.0m / 2.23b)
NOPAT = 1.85b (EBIT 2.42b * (1 - 23.63%))
Current Ratio = 0.77 (Total Current Assets 5.29b / Total Current Liabilities 6.90b)
Debt / Equity = 4.02 (Debt 7.21b / totalStockholderEquity, last quarter 1.80b)
Debt / EBITDA = 2.18 (Net Debt 6.67b / EBITDA 3.06b)
Debt / FCF = 2.59 (Net Debt 6.67b / FCF TTM 2.58b)
Total Stockholder Equity = 1.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.65% (Net Income 2.12b / Total Assets 17.2b)
RoE = 143.6% (Net Income TTM 2.12b / Total Stockholder Equity 1.48b)
RoCE = 30.41% (EBIT 2.42b / Capital Employed (Equity 1.48b + L.T.Debt 6.47b))
RoIC = 17.85% (NOPAT 1.85b / Invested Capital 10.3b)
WACC = 5.11% (E(36.0b)/V(43.2b) * Re(5.60%) + D(7.21b)/V(43.2b) * Rd(3.47%) * (1-Tc(0.24)))
Discount Rate = 5.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.17 | Cagr: -0.76%
[DCF] Terminal Value 76.41% ; FCFF base≈2.50b ; Y1≈2.68b ; Y5≈3.21b
[DCF] Fair Price = 128.5 (EV 49.3b - Net Debt 6.67b = Equity 42.6b / Shares 331.9m; r=8.35% [WACC [floored]]; 5y FCF grow 7.78% → 2.50% )
EPS Correlation: 88.05 | EPS CAGR: 5.87% | SUE: 0.30 | # QB: 0
Revenue Correlation: -96.21 | Revenue CAGR: -7.40% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.01 | Chg30d=-0.49% | Revisions=-40% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.80 | Chg30d=-0.30% | Revisions=-40% | Analysts=14
EPS current Year (2026-12-31): EPS=7.54 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=+0.1% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=7.56 | Chg30d=-0.25% | Revisions=-40% | GrowthEPS=+0.2% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: -73% (up=0, down=8)